Towards Healthcare

Drug-Eluting Balloon Catheters Market Companies, Strategic Expansion Initiatives, Revenue Diversification and Strategic Joint Ventures

Date : 26 September 2025

Drug-Eluting Balloon Catheters Market Leading Companies

Drug-Eluting Balloon Catheters Market Companies

  • Abbott
  • B. Braun Melsungen AG
  • Bard/BD Interventional
  • BIOTRONIK
  • Boston Scientific
  • Concept Medical
  • Cook Medical
  • Edward Lifesciences
  • Gore & Associates
  • Lépine
  • MedAlliance
  • Medtronic
  • Philips
  • Terumo Corporation
  • W. L. Gore & Associates

Drug-Eluting Balloon Catheters Market Growth:

The global drug-eluting balloon catheters market size is calculated at US$ 1.42 billion in 2024, grew to US$ 1.58 billion in 2025, and is projected to reach around US$ 4.02 billion by 2034. The market is expanding at a CAGR of 11.1% between 2025 and 2034.

Drug-Eluting Balloon Catheters Market Size 2024 to 2034

Numerous leaders are leveraging their position in the global market to invest in the development of novel therapies and the latest solutions for severe conditions.

  • In September 2025, Concept Medical Group, a global player in drug-delivery technologies, acquired commercial approval for its flagship MagicTouch Sirolimus-Coated Balloon (SCB) for CAD treatment from ANVISA, Brazil’s Health Surveillance Agency.
  • In February 2025, Teleflex Incorporated, a leading global provider of medical technologies, entered into a definitive agreement to acquire substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG for a predicted cash payment on closing of approximately €760 million.
  • In August 2023, Advanced NanoTherapies received $4M Series A extension from an undisclosed strategic investor for drug-coated balloon development.

Latest Announcements by Industry Leaders

In April 2025, Cordis, a leading player in interventional cardiovascular and endovascular technologies, announced new data from two important peripheral studies that are assessing the SELUTION SLR™ Drug-Eluting Balloon (DEB). Dr. Michael Lichtenberg, Chief of Interventional Angiology, said that this approach will deliver unequivocal clinical advantages in complex patient cohorts.

Recent Developments in the Drug-Eluting Balloon Catheters Market

  • In February 2025, Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, launched its novel product, Serranator SL-PRO™ PTA Serration Balloon Catheter.
  • In March 2024, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is used in treating coronary in-stent restenosis (ISR) in patients with coronary artery disease.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com